CE Information and Faculty Disclosures

• TARGET AUDIENCE
  These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lymphomas.
  
  LEARNING OBJECTIVES

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), and use this information to enhance decision-making for patients.
  • Appraise the rationale for and available data documenting the utility of lenalidomide in combination with rituximab for newly diagnosed and R/R FL, and use this information to counsel patients regarding what role, if any, this regimen should play in their care.
  • Recognize how prior therapeutic exposure and other patient and disease characteristics, including EZH2 mutation status, affect the selection and sequencing of available systemic treatments for R/R FL.
  • Appraise the similarities and differences among commercially available Bruton tyrosine kinase inhibitors, and counsel patients regarding the selection and sequencing of these agents in the management of R/R MCL.
  • Recall existing and emerging efficacy and safety data from clinical trials of approved and investigational CAR (chimeric antigen receptor) T-cell therapies directed at CD19 for R/R B-cell lymphomas, and identify patients who may be candidates for this approach.
  • Understand the FDA-approved indications for tafasitamab/lenalidomide and lisocabtagene maraleucel for patients with R/R DLBCL, and consider how these agents can be appropriately and safely incorporated into clinical practice.
  • Evaluate updated clinical trial data with brentuximab vedotin in combination with AVD (doxorubicin/vinblastine/dacarbazine) to discern how this regimen can be optimally incorporated into front-line management of advanced classical HL.
  • Educate patients about the side effects associated with FDA-approved therapies commonly used in the management of various forms of lymphoma, and provide strategies to prevent or ameliorate these toxicities.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component.
  NCPD credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Stephen M Ansell, MD, PhD
  Professor of Medicine
  Chair, Lymphoma Group
  Mayo Clinic
  Rochester, Minnesota
  
  Contracted Research (to Institution): ADC Therapeutics, Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc.
  
  Robin Klebig, APRN, CNP, AOCNP
  Nurse Practitioner
  Assistant Professor of Medicine
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Novartis and Seagen Inc.
  
  Release date: November 2021
  Expiration date: November 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.